Risperdal Lawsuit News: Gynecomastia Trials to Resume in October, Bernstein Liebhard LLP Reports

September 1, 2015 - The Pennsylvania mass tort litigation overseeing hundreds of Risperdal lawsuits (http://bl.risperdallawsuitcenter.com/) filed on behalf of men and boys who allegedly developed gynecomastia due to its use is set to resume its bellwether trial program in October. According to documents pending in the Philadelphia Court of Common Pleas, two such cases will be presented to juries in October. Pretrial discovery has also begun in 10 additional claims that are expected to go to trial beginning next spring. (In Re: Risperdal Litigation, Case Number 100300296)

"Our Firm is representing a number of Risperdal lawsuit plaintiffs who allegedly experienced excessive male breast growth due to its use. We will be monitoring these upcoming trials closely, as they may provide valuable insight into how juries will decide similar claims," said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide free legal reviews to alleged victims of Risperdal gynecomastia.

Risperdal Gynecomastia Litigation
Risperdal (risperidone) is an atypical antipsychotic drug that is approved by the U.S. Food & Drug Administration (FDA) to treat adult and adolescent schizophrenia, bipolar disorder in adults and children ages 10-to-17, and irritability in children (5-to-16 years of age) with autistic disorder.

Court documents indicate that the medication is currently the subject of more than 1,440 Pennsylvania lawsuits filed on behalf of individuals who allegedly developed gynecomastia and other side effects due to its use. Among other things, plaintiffs allege that Johnson & Johnson and its Janssen Pharmaceuticals unit improperly marketed Risperdal for off-label treatments, including certain pediatric indications that weren't approved until 2006. Specifically, Risperdal gynecomastia plaintiffs claim that the companies failed to warn that patients using the drug may experience a rise in the body's levels of prolactin, a hormone tied to female breast development that can also cause excessive breast growth in men.

Two Risperdal gynecomastia trials were convened in Pennsylvania earlier this year. The first concluded in February, after the jury hearing the case awarded $2.5 million in compensatory damages to an autistic man who was treated with the medication as a child. (Case No. A-196444) The second trial concluded a month later, with jurors finding that patients and doctors were not adequately warned about Risperdal's association with male breast development. However, the jury declined to award any damages to the plaintiff, after they were unable to determine that the drug caused his excessive breast development. (Case No. 130301803) An undisclosed Risperdal settlement was reached in a third gynecomastia case that had been scheduled to go to trial in May. (Case No. 130301812)

Risperdal patients who allegedly developed gynecomastia connected with its use may be eligible to file their own lawsuit. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm's website, or by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com
http://bl.risperdallawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author